New combo pill for high blood pressure enters first human tests
NCT ID NCT07421401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new combination pill (BR1015-A) containing two blood pressure medicines, Fimasartan and Indapamide, in 58 healthy adults. The goal is to see how the body absorbs and processes the drugs and to check for any safety issues. Participants will take the pill once on four separate occasions under fasting conditions. This study does not treat high blood pressure but gathers important information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fimasartan and Indapamide combination tablet
What this could lead to
If successful, this could lead to a new once-daily pill that helps control high blood pressure more conveniently.
What could go wrong
This is a very early (Phase 1) study in only 58 healthy people, not patients. It only checks how the drug is processed and basic safety; it cannot tell us if it actually works for hypertension.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••